T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1776
Teva Pharmaceuticals
TEVA
$42.6B
| $1.06M | ﹤0.01% |
140,354
+3,731
| +3% | +$30.3K |
|
1777
Blue Bird Corp
BLBD
$2.04B
| $1.06M | ﹤0.01% |
+46,919
| New | +$1M |
|
1778
BOK Financial
BOKF
$8.85B
| $1.05M | ﹤0.01% |
12,981
-186
| -1% | -$15.3K |
|
|
KW
1779
DELISTED
Kennedy-Wilson Holdings
KW
| $1.05M | ﹤0.01% |
64,129
+1,675
| +3% | +$26.8K |
|
1780
IonQ
IONQ
$18.2B
| $1.04M | ﹤0.01% |
76,964
+30,514
| +66% | +$254K |
|
|
XHR
1781
Xenia Hotels & Resorts
XHR
$1.73B
| $1.04M | ﹤0.01% |
84,577
+1,287
| +2% | +$16.1K |
|
1782
American Vanguard Corp
AVD
$64M
| $1.04M | ﹤0.01% |
58,134
+28,994
| +99% | +$536K |
|
1783
Corcept Therapeutics
CORT
$12.1B
| $1.04M | ﹤0.01% |
46,643
+832
| +2% | +$19.1K |
|
1784
Futu Holdings
FUTU
$14.7B
| $1.04M | ﹤0.01% |
26,092
-6,829
| -21% | -$291K |
|
1785
Sinclair Inc
SBGI
$1B
| $1.04M | ﹤0.01% |
75,028
+45,984
| +158% | +$759K |
|
1786
Cheesecake Factory
CAKE
$5.57B
| $1.04M | ﹤0.01% |
29,946
+636
| +2% | +$21.1K |
|
1787
Apogee Enterprises
APOG
$897M
| $1.03M | ﹤0.01% |
21,775
+377
| +2% | +$15.7K |
|
|
CBAY
1788
DELISTED
Cymabay Therapeutics
CBAY
| $1.03M | ﹤0.01% |
94,421
+21,810
| +30% | +$203K |
|
1789
Kforce
KFRC
$1.03B
| $1.03M | ﹤0.01% |
16,397
+1,021
| +7% | +$61.5K |
|
1790
BridgeBio Pharma
BBIO
$15.9B
| $1.03M | ﹤0.01% |
59,756
+4,555
| +8% | +$68.5K |
|
1791
Cathay General Bancorp
CATY
$4.31B
| $1.03M | ﹤0.01% |
31,916
+905
| +3% | +$28.7K |
|
1792
Central Garden & Pet Co
CENT
$2.79B
| $1.02M | ﹤0.01% |
33,031
+760
| +2% | +$23.1K |
|
1793
Greif
GEF
$5.03B
| $1.02M | ﹤0.01% |
14,853
+258
| +2% | +$16.6K |
|
1794
AppFolio
APPF
$7.22B
| $1.02M | ﹤0.01% |
5,928
+435
| +8% | +$63.3K |
|
1795
Tennant Co
TNC
$1.15B
| $1.02M | ﹤0.01% |
12,586
+223
| +2% | +$16.8K |
|
|
B
1796
DELISTED
Barnes Group Inc.
B
| $1.02M | ﹤0.01% |
24,188
+574
| +2% | +$23.4K |
|
1797
Asana
ASAN
$2.28B
| $1.02M | ﹤0.01% |
46,235
+3,284
| +8% | +$65.8K |
|
1798
Q2 Holdings
QTWO
$4.13B
| $1.02M | ﹤0.01% |
32,951
+2,100
| +7% | +$55K |
|
1799
ChargePoint
CHPT
$160M
| $1.01M | ﹤0.01% |
5,761
+389
| +7% | +$68.2K |
|
1800
First Interstate BancSystem
FIBK
$3.7B
| $1.01M | ﹤0.01% |
42,482
+530
| +1% | +$13.4K |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.